



## The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.

Guillaume Ploussard, Alexandre de La Taille, Younes Bayoud, Xavier Durand, Stéphane Terry, Evangelos Xylinas, Yves Allory, Francis Vacherot, Claude-Clément Abbou, Laurent Salomon

### ► To cite this version:

Guillaume Ploussard, Alexandre de La Taille, Younes Bayoud, Xavier Durand, Stéphane Terry, et al.. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.. European Urology, 2012, 61 (2), pp.356-62. 10.1016/j.eururo.2011.07.041 . inserm-00661870

HAL Id: inserm-00661870

<https://inserm.hal.science/inserm-00661870>

Submitted on 20 Jan 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

|                                   | <b><i>n=300</i></b> |
|-----------------------------------|---------------------|
| Age, years :                      |                     |
| Mean                              | 63.1                |
| Range                             | 48.6-75.0           |
| PSA, ng/ml :                      |                     |
| Mean                              | 6.0                 |
| Range                             | 0.84-10.0           |
| Prostate volume, ml :             |                     |
| Mean                              | 57.7                |
| Range                             | 18.0-192.0          |
| Volume >50 ml (%)                 | 53.9%               |
| PSA density, ng/ml/gr :           |                     |
| Mean                              | 0.124               |
| Range                             | 0.023-0.380         |
| PSA density >0.15 (%)             | 28.3%               |
| Clinical stage T1c, %             | 100%                |
| <i>Biopsy features</i>            |                     |
| Positive cores, n (%):            |                     |
| 1                                 | 150 (65.2)          |
| 2                                 | 80 (34.8)           |
| Total tumor length on biopsy, mm: |                     |
| Mean                              | 2.48                |
| Range                             | 0.05-15.0           |
| Biopsy Gleason score 6, %         | 100%                |
| <i>RP specimens features</i>      |                     |
| Gleason score, n (%):             |                     |
| 6                                 | 140 (60.8)          |
| 7                                 | 89 (38.7)           |
| 8                                 | 1 (0.4)             |
| Dominant Gleason grade 4, n (%)   | 25 (10.9)           |
| Extraprostatic extension, n (%)   | 28 (12.2)           |
| Seminal vesicle invasion, n (%)   | 1 (0.4)             |
| Positive surgical margins, n (%)  | 32 (13.9)           |
| Follow-up after RP, mo:           |                     |
| Mean                              | 19.9                |
| Range                             | 0.3-89.2            |